INM Stock Whipsaws As Amended Mentari Merger Terms Hit Tape

InMed Pharmaceuticals Inc. stocks have been trading up by 13.64 percent amid heightened optimism over its latest cannabinoid pipeline developments.

Live Update At 17:03:24 EDT: On Wednesday, July 22, 2026 InMed Pharmaceuticals Inc. stock [NASDAQ: INM] is trending up by 13.64%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

INM has been trading like a small-cap biotech textbook. Over the past few weeks, the stock has mostly chopped between roughly $1.50 and $1.70, with a close at $1.66 after a wide intraday range that stretched from $1.49 to $2.33. That kind of range tells traders one thing: liquidity is thin and every headline matters.

Intraday, INM showed extreme volatility, spiking premarket above $5.00 before fading hard into the $1s. For day traders, that’s the exact kind of wild action that can create both huge wins and brutal losses if you are late. The tape shows multiple sharp pops and fades, a sign that short-term momentum traders are in control rather than longer-term holders.

On the fundamentals, InMed Pharmaceuticals reported about $4.9M in revenue over the trailing period, but the company is still deeply unprofitable. Margins are sharply negative, and net income for the latest quarter came in near -$3.0M. Yet INM carries very low debt, a current ratio around 3.1, and more than $5.1M in cash. That balance sheet buys time, but not forever. For traders, this is a classic story-stock setup: weak earnings, decent cash, and a major pending corporate event in the Mentari merger.

Why Traders Are Watching INM’s Amended Mentari Deal

The real story driving INM right now is not last quarter’s loss — it’s the amended all-stock merger agreement with privately held Mentari Therapeutics. InMed Pharmaceuticals has now tweaked that agreement and filed a Form S-4 registration statement and preliminary proxy/prospectus with the SEC. That signals the deal is advancing through the regulatory maze, not falling apart.

For traders, the key word here is “all-stock.” INM is using its shares as currency to buy Mentari. The amendment clarifies how any pre-closing financing will change the share-exchange ratio. Translation: if InMed Pharmaceuticals raises more capital before the merger closes, the pie gets sliced differently between current INM holders and Mentari owners. That is dilution risk in plain English, and traders need to respect it.

The updated terms also clarify the order of deal steps and the intended tax treatment. Those are technical points, but they matter because they reduce uncertainty around how the INM–Mentari structure will look once it is finally done. The boards of both InMed Pharmaceuticals and Mentari have already approved the combination, and the companies are now targeting a Q4 2026 close, subject to shareholder approval and S-4 effectiveness.

That long runway creates a strange mix for traders. On one hand, INM now has a clearer roadmap. On the other, the main catalyst is years away and still tied to multiple conditions. So the stock becomes a trading vehicle around headlines, financing moves, and sentiment, not a near-term merger-arb play. When a thinly traded biotech like InMed Pharmaceuticals drops a deal tweak plus a heavy S-4 filing, fast money moves in, which explains the intraday spikes and crashes you’re seeing on the INM chart.

Conclusion

INM is now a story of structure, not just science. InMed Pharmaceuticals has taken an important step by amending the Mentari Therapeutics merger agreement and pushing a detailed Form S-4 into the SEC pipeline. Traders have more clarity on the mechanics: how pre-closing financing hits the exchange ratio, what the tax treatment is intended to be, and in what order the acquisition chess pieces will move.

But this is not a quick catalyst. With the INM–Mentari deal targeted for Q4 2026 and still depending on shareholder approvals and regulatory sign-offs, the path is long and packed with event risk. In the meantime, InMed Pharmaceuticals remains a small-cap biotech with heavy losses, limited but real cash, and a chart that can swing 100%+ in a single session.

That combination will keep INM on the radar of active traders who thrive on volatility and understand dilution and capital-structure risk. The smart approach is to treat InMed Pharmaceuticals as a trading vehicle, not a promise. As Tim Sykes likes to remind his students, “The market doesn’t care about your hopes. It only cares about price action. Respect the price, cut losses fast, and let the chart tell the story.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”.

This analysis is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks